These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease. Bilello M; Doshi J; Nabavizadeh SA; Toledo JB; Erus G; Xie SX; Trojanowski JQ; Han X; Davatzikos C J Alzheimers Dis; 2015; 48(4):987-94. PubMed ID: 26402108 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
11. Alzheimer's Disease Polygenic Risk Score Is Not Associated With Cognitive Decline Among Older Adults With Type 2 Diabetes. Manzali SB; Yu E; Ravona-Springer R; Livny A; Golan S; Ouyang Y; Lesman-Segev O; Liu L; Ganmore I; Alkelai A; Gan-Or Z; Lin HM; Heymann A; Schnaider Beeri M; Greenbaum L Front Aging Neurosci; 2022; 14():853695. PubMed ID: 36110429 [TBL] [Abstract][Full Text] [Related]
12. White matter hyperintensities and patterns of atrophy in early onset Alzheimer's disease with causative gene mutations. Mao C; Li J; Huang X; Dong L; Liu C; Peng B; Cui L; Gao J Clin Neurol Neurosurg; 2021 Apr; 203():106552. PubMed ID: 33601235 [TBL] [Abstract][Full Text] [Related]
13. A data-driven model of biomarker changes in sporadic Alzheimer's disease. Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC; Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224 [TBL] [Abstract][Full Text] [Related]
14. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112 [TBL] [Abstract][Full Text] [Related]
15. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS; Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035 [TBL] [Abstract][Full Text] [Related]
16. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
17. Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's Disease. Daunt P; Ballard CG; Creese B; Davidson G; Hardy J; Oshota O; Pither RJ; Gibson AM J Prev Alzheimers Dis; 2021; 8(1):78-83. PubMed ID: 33336228 [TBL] [Abstract][Full Text] [Related]
20. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. Ware EB; Faul JD; Mitchell CM; Bakulski KM BMC Med Genomics; 2020 Nov; 13(1):164. PubMed ID: 33143703 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]